Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
-
- Zobair Younossi
- Center for Liver Diseases, Department of Medicine,Inova Fairfax Hospital,Falls Church,VA
-
- Frank Tacke
- Department of Medicine III,University Hospital Aachen,Aachen,Germany
-
- Marco Arrese
- Departamento de Gastroenterolog´ıa,Escuela de Medicina, Pontificia Universidad Catolica de Chile,Santiago,Chile
-
- Barjesh Chander Sharma
- Department of Gastroenterology,GIPMER,New Delhi,India
-
- Ibrahim Mostafa
- Theodor Bilharz Research Institute,Cairo,Egypt
-
- Elisabetta Bugianesi
- Division of Gastroenterology,University of Torino,Torino,Italy
-
- Vincent Wai‐Sun Wong
- Institute of Digestive Disease,The Chinese University of Hong Kong,Hong Kong
-
- Yusuf Yilmaz
- Department of Gastroenterology,Marmara University,School of Medicine,Istanbul,Turkey
-
- Jacob George
- Department of Gastroenterology & Hepatology,Westmead Hospital, University of Sydney,Australia
-
- Jiangao Fan
- Center for Fatty Liver, Department of Gastroenterology,Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai,China
-
- Miriam B. Vos
- Department of Pediatrics, School of Medicine and Nutrition Health Sciences,Emory University,Atlanta,GA
抄録
<jats:p>Over the past 2 decades, nonalcoholic fatty liver disease (NAFLD) has grown from a relatively unknown disease to the most common cause of chronic liver disease in the world. In fact, 25% of the world’s population is currently thought to have NAFLD. Nonalcoholic steatohepatitis (NASH) is the subtype of NAFLD that can progress to cirrhosis, hepatocellular carcinoma (HCC), and death. NAFLD and NASH are not only found in adults—there is also a high prevalence of these diseases in children and adolescents. Because of the close association of NAFLD with type 2 diabetes (T2DM) and obesity, the latest models predict that the prevalence of NAFLD and NASH will increase, causing a tremendous clinical and economic burden and poor patient‐reported outcomes. Nonetheless, there is no accurate noninvasive method to detect NASH, and treatment of this disease is limited to lifestyle modifications. To examine the state of NAFLD among different regions and understand the global trajectory of this disease, an international group of experts came together during the 2017 American Association for the Study of Liver Diseases Global NAFLD Forum. We provide a summary of this forum and an assessment of the current state of NAFLD and NASH worldwide.</jats:p>
収録刊行物
-
- Hepatology
-
Hepatology 69 (6), 2672-2682, 2019-05-29
Ovid Technologies (Wolters Kluwer Health)